Overview
InMode Q2 revenue rises to $95.6 mln, missing analyst expectations
EPS for Q2 meets analyst expectations at $0.42 per share
Co's international sales offset U.S. market challenges
Outlook
Company anticipates full-year non-GAAP EPS of $1.55 to $1.59
InMode expects 2025 non-GAAP income from operations of $93 mln to $98 mln
Company cites macroeconomic uncertainty and cautious consumer behavior as headwinds
Result Drivers
MACROECONOMIC UNCERTAINTY - Co cites ongoing macroeconomic uncertainty and cautious consumer behavior impacting Q2 results
INTERNATIONAL SALES - Record high sales in Europe offset challenges in U.S. market, per CEO Moshe Mizrahy
TARIFF IMPACT - Potential 2% to 3% impact on gross margins due to U.S. tariffs, per CFO Yair Malca
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $95.60 mln | $96.50 mln (7 Analysts) |
Q2 EPS | Meet | $0.42 | $0.42 (7 Analysts) |
Q2 Net Income | Miss | $26.74 mln | $28.80 mln (4 Analysts) |
Q2 Gross Margin | 80.0% | ||
Q2 Pretax Profit | Miss | $30.94 mln | $32.10 mln (5 Analysts) |
Q2 Operating Expenses | $53.57 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Inmode Ltd is $16.00, about 10.6% above its July 29 closing price of $14.31
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago
Press Release: ID:nPn8JVtBHa
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)